Record-Breaking Revenue and Growth
SI-BONE delivered a record $49 million in worldwide revenue for Q4 2024, representing growth exceeding 26%. U.S. revenue increased by 28% to $46.9 million driven by strong demand from nearly 1,400 active physicians.
Product Launch Success
Granite 9.5 and TNT launches exceeded expectations, with Granite 9.5 gaining strong momentum and TNT seeing rapid adoption. Both products are expected to be major growth drivers in 2025.
Positive Adjusted EBITDA
SI-BONE achieved positive adjusted EBITDA of $1.9 million in Q4 2024, a significant improvement from the previous year's adjusted EBITDA loss of $4.8 million.
Strong Physician Engagement
Record number of physicians trained in 2024, with nearly 2,000 U.S. physicians performing at least one procedure. Active physicians grew by 23%, with a 40% increase in physicians performing multiple procedure types.
Breakthrough Device Designations
Received breakthrough device designation from the FDA for a new novel implant system, marking SI-BONE's third BDD product, positioning the company as a leader in innovation.